Latest Articles

Publication Date
New perspectives in managing chronic pelvic pain in Endometriosis: the role of GnRH antagonists versus dienogest.

Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and …

Published: April 9, 2026, midnight
Clinical Efficacy of Dienogest for Symptomatic Adenomyosis.

Background: This study was conducted to assess whether medical treatment with dienogest (DNG) is effective in women with symptomatic adenomyosis. Methods: This single-center, retrospective study included patients with symptomatic adenomyosis …

Published: April 6, 2026, midnight
Clinical and endocrine effects of pharmacological therapy in endometriosis: a systematic review and meta-analysis.

Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …

Published: April 1, 2026, midnight
Synergistic effects of melatonin and dienogest on pain relief in endometriosis: a randomized controlled trial.

Endometriosis affects 5-10% of reproductive-aged women and is characterized by chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. Standard hormonal therapies, such as dienogest, effectively manage symptoms, but are often associated …

Published: March 31, 2026, midnight
Effectiveness of BMMSC and Dienogest on IL-1β, IL-8 Expression and Lesion Area in Endometriosis Mice.

Endometriosis is a chronic estrogen-dependent inflammatory disease that impairs fertility and quality of life. Dienogest, the current standard therapy, provides symptom relief but does not correct immune imbalance or prevent …

Published: March 17, 2026, midnight
Repeatedly occurring retrograde menstruation intensifies central sensitization driven by neuroinflammation in endometriosis models.

This study investigated how chronic pelvic pain (CPP) develops using rhesus macaques with naturally occurring endometriosis and a multiple-lesion induction mouse model (MIM), as repeated retrograde menstruation is considered an …

Published: March 17, 2026, midnight
Comment on "Dienogest treatment in women with endometriosis: A retrospective cohort study in Taiwan".

Published: March 13, 2026, midnight
Three-dimensional patient-derived endometriosis model for drug evaluation.

Endometriomsis (EMs) is a complex and chronic gynecological disease characterized by distressing symptoms. Its pathogenesis remains unknown, and there is no effective treatment. Therefore, establishing patient-derived models is crucial for …

Published: March 2, 2026, midnight
The inhibition of deep peritoneal endometriosis by Andrographolide through macrophage M1 activity in an endometriosis mice model.

This study aims to demonstrate that Andrographolide, an herbal immunostimulant, can influence M1 macrophages to inhibit inflammation, including the growth of endometriosis caused by inflammation. This study evaluates the effects …

Published: Feb. 27, 2026, midnight
Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis.

This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …

Published: Feb. 15, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!